



## Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024

Mar  
7

*Company to host conference call and webcast at 8:30 a.m. EDT*

CARMIEL, Israel, March 7, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx<sup>®</sup> plant cell-based protein expression system, today announced that it will release its financial results for the fiscal year ended December 31, 2023 and provide a business update on Thursday, March 14, 2024.



Management will host a conference call with investors to discuss the financial results and provide a business update.

### Conference Call Details:

**Date:** Thursday, March 14, 2024  
**Time:** 8:30 a.m. Eastern Daylight Time (EDT)  
**Toll Free:** 1-877-423-9813  
**International:** 1-201-689-8573  
**Israeli Toll Free:** 1-809-406-247  
**Conference ID:** 13744193  
**Call me™:** <https://tinyurl.com/4pkhcxcj>

The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.

### Webcast Details:

Company Link: <https://protalixbiotherapeutics.gcs-web.com/events0>  
Webcast Link: <https://tinyurl.com/mumnf9da>  
Conference ID: 13744193

Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.

### About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio<sup>®</sup>, was approved by both the FDA and the European Medicines Agency in May 2023.

Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX-115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others.

### Investor Contact

Mike Moyer, Managing Director  
LifeSci Advisors  
+1-617-308-4306  
[mmoyer@lifesciadvisors.com](mailto:mmoyer@lifesciadvisors.com)

Logo - [https://mma.prnewswire.com/media/999479/Protalix\\_Biotherapeutics\\_Logo.jpg](https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg)

 View original content: <https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-fiscal-year-2023-financial-and-business->

[results-on-march-14-2024-302082682.html](https://www.sec.gov/edgar/disclosure/cfr/title17/2024/302082682.html)

SOURCE Protalix BioTherapeutics, Inc.